within Pharmacolibrary.Drugs.ATC.J;

model J06BD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0027333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.00458,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Sotrovimab is a recombinant human monoclonal antibody that targets the spike protein of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild-to-moderate COVID-19 in patients at risk of developing severe disease. Sotrovimab received Emergency Use Authorization (EUA) and conditional approvals in various countries during the COVID-19 pandemic.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult healthy volunteers and patients with mild to moderate COVID-19 infection.</p><h4>References</h4><ol><li><p>Dulhunty, JM, et al., &amp; Lipman, J (2024). Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. <i>JAMA</i> 332(8) 629–637. DOI:<a href=&quot;https://doi.org/10.1001/jama.2024.9779&quot;>10.1001/jama.2024.9779</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38864155/&quot;>https://pubmed.ncbi.nlm.nih.gov/38864155</a></p></li><li><p>Moya, J, et al., &amp; Acloque, G (2023). Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial. <i>Open forum infectious diseases</i> 10(7) ofad344–None. DOI:<a href=&quot;https://doi.org/10.1093/ofid/ofad344&quot;>10.1093/ofid/ofad344</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37520411/&quot;>https://pubmed.ncbi.nlm.nih.gov/37520411</a></p></li><li><p>Sager, JE, et al., &amp; Reyes, M (2023). Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 12(6) 853–864. DOI:<a href=&quot;https://doi.org/10.1002/psp4.12958&quot;>10.1002/psp4.12958</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36922886/&quot;>https://pubmed.ncbi.nlm.nih.gov/36922886</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J06BD05;
